Medtronic's Resolute DES beats Boston's Taxus in Japanese study
This article was originally published in Clinica
Executive Summary
Medtronic's new-generation drug-eluting stent Resolute has beaten Boston Scientific's Taxus DES, a rival product and one of the established brands in the DES market, in a Japanese clinical study. The positive results should help Medtronic obtain approval to market Resolute in the world's second largest medtech market.